Abbott Laboratories 2020 Form 10-K Summary
Business context and reporting period
Abbott Laboratories filed its Form 10-K for the fiscal year ended December 31, 2020. Abbott is a diversified global health care company operating through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. International sales represented approximately 62% of consolidated net sales, and Abbott employed approximately 109,000 people in more than 160 countries.
The COVID-19 pandemic materially affected results. Demand for COVID-19 diagnostic tests increased substantially, while routine diagnostic testing and cardiovascular and neuromodulation procedures declined. Nutritionals and diabetes care were comparatively resilient.
Key financial metrics
| Metric | 2020 | 2019 | Change or comment |
|---|---|---|---|
| Net sales | $34.608 billion | $31.904 billion | Up 8.5%; volume up 10.2%, offset by unfavorable foreign exchange of 1.3% |
| Operating earnings | $5.357 billion | $4.532 billion | Operating margin increased to 15.5% from 14.2% |
| Gross margin | 50.5% | 52.5% | Declined due to sales mix, COVID-19 inefficiencies, amortization, impairment, and foreign exchange |
| Earnings from continuing operations | $4.471 billion | $3.687 billion | Effective tax rate was 10.0% versus 9.6% |
| Net earnings | $4.495 billion | $3.687 billion | Includes $24 million from discontinued operations |
| Diluted EPS | $2.50 | $2.06 | Continuing-operations diluted EPS was $2.49 versus $2.06 |
| Net cash from operating activities | $7.901 billion | $6.136 billion | Increased primarily from higher operating earnings and lower interest, integration, and restructuring payments |
| Capital expenditures | $2.177 billion | $1.638 billion | Increase primarily reflected capacity for COVID-19 diagnostic tests |
| Cash and cash equivalents | $6.838 billion | $3.860 billion | Cash and short-term investments totaled approximately $7.1 billion |
| Total debt | Approximately $18.7 billion | Approximately $18.1 billion | Includes $18.527 billion of long-term debt and $213 million of short-term borrowings |
| Working capital | $8.5 billion | $4.8 billion | Improved primarily from higher cash and lower current debt |
Segment performance and material changes
- Diagnostic Products: Sales increased 40.1% to $10.805 billion excluding the effect of foreign exchange. COVID-19 testing-related sales were approximately $3.884 billion, including $2.593 billion from Rapid Diagnostics and $1.023 billion from Molecular Diagnostics. Segment operating earnings increased 94.8% to $3.725 billion, and operating margin reached 34.5%.
- Medical Devices: Sales declined 3.7% to $11.787 billion, excluding a 0.1% favorable foreign-exchange effect. Cardiovascular and neuromodulation sales declined as procedures were deferred, while Diabetes Care sales increased 29%, driven by FreeStyle Libre. FreeStyle Libre sales totaled $2.635 billion, up 42.6% excluding foreign exchange. Segment operating earnings declined 19.4%, and margin fell to 25.8% from 30.8%.
- Nutritional Products: Sales increased 3.2% on a reported basis and 4.7% excluding foreign exchange to $7.647 billion. Adult nutrition sales grew strongly, while international pediatric nutrition was pressured by market conditions in Greater China.
- Established Pharmaceutical Products: Sales declined 4.1% on a reported basis but increased 1.9% excluding foreign exchange to $4.303 billion. The pandemic and foreign exchange affected emerging-market demand. Segment operating margin declined to 18.5%.
- Consolidated operating margin improved despite the lower gross margin, reflecting higher COVID-19 diagnostic volumes and lower acquisition and restructuring costs. Research and development expense was $2.420 billion, essentially flat with 2019.
Cash flow, liquidity, debt, and capital allocation
- Operating cash flow of $7.901 billion exceeded capital expenditures of $2.177 billion and dividends paid of $2.560 billion.
- Abbott issued $1.3 billion of senior notes in June 2020 and repaid approximately $1.3 billion of euro-denominated notes at maturity in September 2020.
- Abbott had access to up to $5 billion under a new unsecured five-year revolving credit agreement maturing in November 2025. Management expected to maintain an investment-grade rating; year-end ratings were A from Standard & Poor’s and A3 from Moody’s.
- Abbott declared dividends of $1.53 per share in 2020 versus $1.32 in 2019. In December 2020, it increased the quarterly dividend 25% to $0.45 per share, effective with the February 2021 payment.
- Abbott repurchased approximately $173 million of shares during 2020 and had approximately $3.097 billion remaining under authorized repurchase programs at December 31, 2020.
Outlook, commentary, risks, and unusual items
- Management planned to continue meeting demand for COVID-19 tests and to invest in Diagnostics, Diabetes Care, Structural Heart, Electrophysiology, Heart Failure, nutrition, and emerging-market pharmaceuticals.
- Abbott expected 2021 research and development spending to approximate 7.0% of total sales. The filing did not provide a specific 2021 sales or earnings guidance range.
- COVID-19 remained a significant uncertainty. Emergency Use Authorizations for several diagnostic products generally last for the duration of the public health emergency and may be terminated or revoked. Routine testing and elective procedures could remain depressed or recover unevenly by geography.
- Other principal risks include regulatory approval and compliance, reimbursement and pricing pressure, product safety and liability, intellectual property expiry or litigation, manufacturing and supply-chain disruptions, cybersecurity and data privacy, foreign exchange, international operations, and acquisition integration.
- Reported unusual items included approximately $100 million of litigation settlement income, approximately $115 million of equity investment impairments, $148 million of Medical Devices intangible-asset impairments, and a $55 million in-process research and development impairment.
- Legal and environmental proceedings were estimated to have a possible loss range of $90 million to $120 million, with approximately $105 million accrued at year-end. Management did not expect the ultimate resolution to materially affect the company.
- Remaining contractual obligations totaled approximately $37.4 billion, including $18.5 billion of long-term debt, $9.0 billion of debt interest, $4.8 billion of purchase commitments, and $3.8 billion of other long-term liabilities.
- The audit opinion was unqualified, and management and the independent auditor concluded that internal control over financial reporting was effective. The critical audit matter concerned approximately $1.2 billion of unrecognized tax benefits.
Important facts for investors to verify
- Whether COVID-19 diagnostic sales remain at 2020 levels as testing demand, competition, pricing, and emergency authorizations evolve.
- The pace of recovery in routine diagnostic testing and cardiovascular and neuromodulation procedures.
- FreeStyle Libre growth and the effect of competition and reimbursement on Diabetes Care margins.
- Debt repayment requirements, interest expense, pension funding, and the ability to sustain dividend growth and share repurchases.
- Sales rebate assumptions: rebates and chargebacks were approximately $3.3 billion in 2020, and a one-percentage-point increase in the rebate rate would reduce net sales by approximately $166 million.
- Exposure to foreign exchange, emerging-market economic conditions, regulatory changes, product liability, cybersecurity, and unrecognized tax benefits.